NCT01813812View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034

PHASE3UnknownINTERVENTIONAL
Enrollment

492

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2013

Conditions
Acute GastritisChronic Gastritis
Interventions
DRUG

DA-6034

DRUG

Rebamipide 300mg

Trial Locations (1)

110-744

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Dong-A Pharmaceutical Co., Ltd.

INDUSTRY

NCT01813812 - A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 | Biotech Hunter | Biotech Hunter